Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chipotle Mexican Grill, Inc. (CMG) vs TG Therapeutics Inc (TGTX) Price & Performance

Chipotle Mexican Grill, Inc.Trade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Chipotle Mexican Grill, Inc. vs TG Therapeutics Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $36.26 (market cap $46.73B), while TG Therapeutics Inc trades at $54.76 (market cap $8.41B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 5.6× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.

CMGTGTX
Market Cap
$46.73B$8.41B
Sector
Consumer CyclicalHealth
52-Week High
$53.95$59.06
52-Week Low
$28.17$26.39
Enterprise Value
$51.11B$8.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chipotle Mexican Grill, Inc.

Chipotle Mexican Grill (CMG) trades at $36.63, up 3.91% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $36 and resistance at $37-38. Recent earnings beats and international expansion into Mexico highlight growth potential, though valuation remains elevated with a P/E of 33.61. Analyst consensus is strongly bullish with 70% buy ratings and a $40.43 price target.

CMG offers growth exposure through international expansion and operational excellence, but faces risks from premium valuation and margin pressures. Revenue growth has slowed to 5.3% in 2025 from 15.1% in 2023, while net margins declined to 12.87%. The stock's premium multiple requires sustained execution to justify current levels amid competitive and inflationary pressures.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.

Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Chipotle Mexican Grill, Inc.

Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.

Read more on CMG

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX